Cannabinoids Found to Reduce 90% of Skin Cancer in Just 20 Weeks, According to New Study
A new study conducted by the Tokyo Metropolitan Institute of Public Health, and published in the newest issue of the Journal of Pharmacy and Pharmacology, has found that cannabinoids can reduce up to 90% of skin cancer in just a 20 week period.
For the study, researchers used synthetic cannabinoids (natural, cannabis-derived cannabinoids are typically even more effective) on mice with skin cancer in a 20 week study, and found that the cannabinoids had a hugely positive effect, reducing skin cancer by up to 90% as well as “inhibiting tumor promotion”.
This is the first report indicating the structure–activity relationships for the anti-inflammatory activity of synthetic cannabinoids on TPA-induced inflammation in mice. Naphthoylindoles, JWH-018, -122 and -210 [synthetic cannabinoids], had the most potent anti-inflammatory activity and also markedly inhibited tumour promotion by TPA in the two-stage mouse skin carcinogenesis model. The present results suggest that synthetic cannabinoids, such as JWH-018, -122 and -210, may be used as cancer chemopreventive agents in the future.
How was it administered? Topically?
Cannabinoids are a class of diverse chemical compounds that activate cannabinoid receptors on cells that repress neurotransmitter release in the brain. These receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (produced chemically by humans). The most notable cannabinoid is the phytocannabinoid ∆9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis. Cannabidiol (CBD) is another major constituent of the plant, representing up to 40% in its extracts. There are at least 85 different cannabinoids isolated from cannabis, exhibiting varied effects.